SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABS
· Real-Time Price · USD
2.19
-0.02 (-0.90%)
At close: Aug 15, 2025, 3:49 PM
-0.90% (1D)
| Bid | 2.17 |
| Market Cap | 22.8M |
| Revenue (ttm) | 377.83K |
| Net Income (ttm) | -34.28M |
| EPS (ttm) | -3.99 |
| PE Ratio (ttm) | -0.55 |
| Forward PE | -1.26 |
| Analyst | Buy |
| Ask | 2.25 |
| Volume | 72,151 |
| Avg. Volume (20D) | 1,431,246 |
| Open | 2.17 |
| Previous Close | 2.21 |
| Day's Range | 2.17 - 2.25 |
| 52-Week Range | 1.00 - 6.60 |
| Beta | 0.54 |
About SABS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SABS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SABS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
SAB Biotherapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-3.33%
SAB Biotherapeutics shares are trading lower after...
Unlock content with
Pro Subscription
3 weeks ago
+5.06%
SAB Biotherapeutics shares are trading higher after the company announced it has raised $175 million via an oversubscribed private placement to fund its Phase 2 SAFEGUARD trial.
